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Clinical PerspectiveWhat Is New?In a prospective cohort of diabetic patients, none of 6 different biomarkers of oxidative stress was significantly associated with the occurrence of major adverse cardiovascular events.What Are the Clinical Implications?To date, despite physiopathological relevance and promising preclinical data, no redox biomarker displays enough accuracy to be used in clinical practice for cardiac risk stratification.

 {#jah32947-sec-0008}

Prognosis in type 2 diabetes mellitus (T2D) is mainly dominated by adverse cardiovascular events.[1](#jah32947-bib-0001){ref-type="ref"} For years, research has focused on the development of predictive tools that could improve the accuracy of risk prediction and individual risk stratification beyond traditional risk factors. Two main issues stand out with regard to precision medicine: (1) improvement of risk stratification at an individual level to optimize primary or secondary prevention and (2) identification of potential therapeutic targets through modification of these marker levels.

Several candidates have been studied, such as clinical findings and additional examinations including circulating biomarkers.[2](#jah32947-bib-0002){ref-type="ref"} In this regard, translational studies have identified redox biomarkers as potential targets, based on the hypothesis that excessive oxidative stress could drive disease development and/or progression.[3](#jah32947-bib-0003){ref-type="ref"} These markers usually include the sources of reactive oxygen species (ROS), ROS levels, and molecules that have been modified by interactions with ROS. ROS excess was proposed as a primary mechanism in diabetic complications,[4](#jah32947-bib-0004){ref-type="ref"} and ROS‐derived biomarkers are therefore logical candidate markers for diabetic complications.

In spite of their biological relevance and promising observational clinical results for some of these biomarkers such as myeloperoxidase,[5](#jah32947-bib-0005){ref-type="ref"} protein and lipid oxidation,[6](#jah32947-bib-0006){ref-type="ref"} advanced glycation end products (AGEs),[7](#jah32947-bib-0007){ref-type="ref"} and their soluble receptor,[8](#jah32947-bib-0008){ref-type="ref"} none of them has reached clinical application. This could be partly due to the lack of data, the complexity of the redox balance, and the high level of interaction between these markers and some known risk factors (age, renal failure, smoking, inflammatory disease, drugs). Conversely, several markers have only been studied in other settings than risk stratification, such as ischemia‐modified albumin (IMA),[9](#jah32947-bib-0009){ref-type="ref"}, [10](#jah32947-bib-0010){ref-type="ref"} carbonyl moieties,[11](#jah32947-bib-0011){ref-type="ref"}, [12](#jah32947-bib-0012){ref-type="ref"} or advanced oxidation protein products (AOPP).[13](#jah32947-bib-0013){ref-type="ref"}, [14](#jah32947-bib-0014){ref-type="ref"} Interestingly, these oxidative modifications of proteins may cause cell dysfunction, accelerate cell death and tissue injury, and thus represent promising biomarkers of oxidative stress that closely reflect the redox imbalance associated with cardiovascular disease.[15](#jah32947-bib-0015){ref-type="ref"}

Last, some pathophysiologically relevant biomarkers are at an early stage of their development, with a lack of clinical data in humans in the field of atherosclerosis, including measurement of total reductive capacity of plasma (TRCP) or oxidative hemolysis inhibition assay (OxHLIA)[16](#jah32947-bib-0016){ref-type="ref"} and could be promising candidates. A better understanding of the relationship between circulating concentrations of markers of oxidative stress and cardiovascular events is therefore needed, along with an investigation of novel biomarkers.

The aim of our study was to investigate the additional prognostic value of 6 different measurements of oxidative stress level (AGEs, AOPP, carbonyls, IMA, TRCP, and OxHLIA), alone or in combination, beyond the traditional risk factors for predicting major cardiovascular outcome in patients with T2D.

Materials and Methods {#jah32947-sec-0009}
=====================

The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.

Study Participants {#jah32947-sec-0010}
------------------

The SURDIAGENE (Survie, Diabete de type 2 et Genetique) study is a prospective cohort designed to identify the determinants of microvascular and macrovascular diabetic complications in T2D and has been described previously.[17](#jah32947-bib-0017){ref-type="ref"}, [18](#jah32947-bib-0018){ref-type="ref"}, [19](#jah32947-bib-0019){ref-type="ref"} Patients aged ≥18 years with a definite diagnosis of T2D for ≥2 years were recruited (2002‐2011) in a study with regular follow‐up every second year since 2007. The main exclusion criteria were evidence of nondiabetic kidney disease and/or follow‐up duration \<1 month. The Poitiers University Hospital Ethics Committee approved the SURDIAGENE study. All participants gave written informed consent.

Clinical Data {#jah32947-sec-0011}
-------------

Clinical data were obtained at inclusion from the patients. History of macrovascular disease was defined by any of the following events in the patient medical record: myocardial infarction, stable angina, stroke or transient ischemic attack, and coronary or carotid artery revascularization. History of hypertension was defined by blood pressure ≥140/90 mm Hg at inclusion and/or antihypertensive treatment. Electrocardiographic left ventricular hypertrophy was defined by the presence of at least 1 of the following criteria: Sokolow‐Lyon \>35 mm, Gubner‐Ungerlaider \>25 mm, or sex‐adjusted Cornell product \>2440 mm·ms.

Estimated glomerular filtration rate (eGFR) was calculated according to the CKD‐EPI (Chronic Kidney Disease Epidemiology Collaboration) equation. Chronic kidney disease stages were defined as follows: stage 1, eGFR ≥90 mL/min per 1.73 m^2^; stage 2, eGFR 89.9 to 60 mL/min per 1.73 m^2^; stage 3, eGFR ≥59.9 to 30 mL/min per 1.73 m^2^; stage 4, 29.9 to 15 mL/min per 1.73 m^2^; and stage 5, eGFR \<15 mL/min per 1.73 m^2^ or renal replacement therapy. The urinary albumin‐to‐creatinine ratio was considered abnormal if it was above 30 mg/mmol. Drug prescriptions were assessed on the day of inclusion.

Biobanking {#jah32947-sec-0012}
----------

Blood samples and second morning urines were obtained after an overnight fast and stored at −80°C until use at the CHU Poitiers biobanking facility, having undergone only 1 prior freeze‐thaw cycle (CRB0033‐00068).

Serum and urine creatinine and urinary albumin were measured by nephelometry on a Modular System P (Roche Diagnostics GmbH, Mannheim, Germany). Glycated hemoglobin was determined using a high‐performance liquid chromatography method: ADAMS A1C HA‐8160 analyzer (Menarini, Florence, Italy). Total and HDL‐cholesterol and triglyceride concentrations were measured with enzymatic methods. LDL‐cholesterol was calculated using the Friedewald formula.

Biological Determinations of Redox Biomarkers {#jah32947-sec-0013}
---------------------------------------------

Venous blood samples were collected into EDTA‐containing tubes. Samples were centrifuged twice for 20 minutes at 2500*g*, recollecting the supernatant of the first centrifugation to be used in the second centrifugation step. For each sample, 300 mL of plasma was aliquoted into 96‐well plates and immediately frozen at −80°C. Absorbance intensity at 280 nm was used to measure total protein concentration.

### Fluorescent AGEs {#jah32947-sec-0014}

Fluorescent AGEs were assessed using a black 96‐well plate spectrofluorometer (Fluostar Omega, BM6, Labtech, Ortenberg, Germany). Briefly, 100 μL of 1:5 diluted plasma was placed in 1 of the wells of a 96‐well plate, and the fluorescence intensity was read at 460 nm after excitation at 355 nm. Results were expressed as arbitrary units (AU).

### Advanced Oxidation Protein Products {#jah32947-sec-0015}

The concentration of AOPPs was obtained by spectrophotometry as previously described.[20](#jah32947-bib-0020){ref-type="ref"} A chloramine‐T solution was used as a standard in each experiment. Plasma samples were diluted 1:10 (final volume 100 mL), and 20 μL of acetic acid was added to samples and to the chloramine‐T solution just before the absorbance intensity was read at 340 nm. Results were expressed as micromoles per liter of chloramine‐T equivalents. Because 529 AOPP samples were below the detection limit of the assay in the performance laboratory, analyses involving this biomarker were categorized as either below the limit of detection (undetected category), below the median of detectable values (detected \<median category), or above the median (detected ≥median category).

### Oxidative Hemolysis Inhibition Assay {#jah32947-sec-0016}

OxHLIA is based on inhibition of free radical--induced membrane damage in erythrocytes by antioxidants present in plasma. For all experiments, erythrocytes were obtained from the same healthy volunteer and collected in EDTA tubes. Red blood cells were isolated by centrifugation (1000*g* for 5 minutes) and subsequently washed 3 times with 0.15 mol/L NaCl. Plasma samples were diluted 1:200 with 0.15 mol/L NaCl, and 100 mL was placed into 96‐well plates. Then, 100 μL of 1:50 diluted red blood cells (about 1×10^8^ erythrocytes) was added to the samples. Finally, 40 mL of a 0.5 mol/L solution of 2,2′‐azo‐bis‐(2‐amidinopropane) dihydrochloride was used to induce red blood cell peroxidation, and the rate of hemolysis was determined at 37°C by spectrophotometry measuring the absorbance at 450 nm every 10 minutes for 16 hours. Results were expressed as 50% of maximal hemolysis time (in minutes) and were obtained using a nonlinear regression in which the data were fit to a Boltzmann sigmoid equation.

### Enzyme‐Linked Immunosorbent Assay Carbonyl {#jah32947-sec-0017}

The degree of carbonylation in plasma was determined by enzyme‐linked immunosorbent assay, based on the recognition of protein‐bound 2,4‐dinitrophenylhydrazine in carbonylated proteins with an anti‐DNP antibody as previously described with slight modifications.[21](#jah32947-bib-0021){ref-type="ref"} Each sample was prepared as follows: 2 μg of total plasma protein was diluted in 10 μL 0.1 mol/L Na~2~CO~3~ buffer (pH 10.35) and 10 μL of 10 mmol/L DNPH (2,4‐dinitrophenylhydrazine in 6 mol/L guanidine hydrochloride, 0.5 mol/L potassium phosphate, pH 2.5) were added to the sample. After 20 minutes of incubation, samples were diluted again to 1:50 in 0.1 mol/L Na~2~CO~3~ buffer. Standards of oxidized and reduced BSA were prepared as indicated by the manufacturer (Oxiselect^™^, Protein Carbonyl ELISA Kit, Cell Biolabs, Inc, San Diego, CA) (carbonyl concentration range 0.375‐7.5 nmol/mg) and modified by 10 mmol/L DNPH for 20 minutes before dilution to 1:50 in 0.1 mol/L Na~2~CO~3~ buffer. MaxiSorp 96‐well plates (Nunc, Roskilde, Denmark) were coated with 100 μL of the antigen solution (samples and standard curve) overnight at 4°C. The coating solution was discarded, and the wells were first 4 times with 250 μL PBS:ethanol 1:1 and then 3 times with PBS. Unspecific sites were blocked by adding 200 μL of 5% nonfat dry milk in PBS/Tween 0.05% for 1.5 hours at room temperature. The wells were then washed 3 times with 250 μL PBS, and the appropriate antibody was added (100 μL of mouse anti‐DNP, Sigma D8406; diluted 1:2000 in Na~2~CO~3~ 0.1 mol/L buffer). After 2 hours of incubation at room temperature, the wells were washed 5 times with 250 μL PBS/Tween 0.05% before addition of 100 μL of the secondary horseradish peroxidase--conjugated antibody (sheep anti‐mouse NXA931, GE Healthcare, Chicago, IL) diluted 1:4000 in Na~2~CO~3~ 0.1 mol/L buffer for 1 hour at room temperature.

Finally, the wells were washed 5 times with 250 μL PBS/Tween 0.05% before addition of 100 μL of TMB solution per well and 100 μL of stop solution (HCl) when the development of the color was sufficient. The absorbance (optical density) was read at 450 nm. The concentration of the samples was calculated from the standard curve.

### Total Reductive Capacity of Plasma {#jah32947-sec-0018}

To measure the antioxidant capacity of plasma, the Folin‐Ciocalteu method was performed as previously described, with slight modifications. Gallic acid was used as a standard. Briefly, 20 μL of plasma was precipitated with 60 μL of methanol. After centrifugation for 5 minutes at 14 000*g*, the resulting supernatant (25 μL) was transferred to a 96‐well plate, and 125 μL of 1:10 Folin reagent (Sigma, St. Louis, MO) was added. Then, 100 μL of Na~2~CO~3~ 0.1 mol/L was added, and the plate was incubated for 5 minutes at 50°C in a shaker. Next, the plate was cooled down for 5 minutes at 4°C, and the absorbance was measured at 760 nm in a plate reader. Gallic acid (Sigma) was used as a standard, and results were expressed as gallic acid equivalents.

### Ischemic Modified Albumin {#jah32947-sec-0019}

This assay is based on the decreased capacity of IMA to bind metals, in this case cobalt. Twenty microliters of 1:4--diluted samples were added to a 96‐well plate along with 15 μL of 0.1% cobalt solution and 125 μL of PBS. The plate was incubated for 15 minutes at 37°C, and the absorbance was immediately measured at 470 nm in a plate reader. Then, 20 μL of a 1.5 mg/mL DTT solution was added to the wells (solution becomes yellow), and after 2 minutes, 20 μL of 0.9 mol/L NaCl was added to stop the reaction. A second reading was performed in order to calculate the increment in the absorbance. Results were expressed as an IMA index.

Outcomes {#jah32947-sec-0020}
--------

Clinical events and biological data were recorded prospectively from patients' hospital records and interviews with general practitioners every second year since 2007. The end point was the first major adverse cardiovascular event (MACE), a composite of cardiovascular death, nonfatal acute myocardial infarction or nonfatal stroke. An independent adjudication committee centrally reviewed each outcome according to international definitions of clinical outcomes.

Statistical Analyses {#jah32947-sec-0021}
--------------------

Means±SD were presented for normally distributed variables and medians (25th to 75th percentile) for nonnormally distributed variables. For regression analyses, we log‐transformed all biomarker concentrations with skewed distributions. Spearman correlations were used to assess the relationships between biomarkers and clinical characteristics.

Kaplan‐Meier survival curves for the outcomes of MACE were plotted by tertiles of biomarker concentrations/activity and by the 3 categories of AOPP. Cox proportional hazards models were used to estimate the effect of each biomarker on the risk of MACE with the biomarkers divided into tertiles/categories or logarithmically transformed. Hazard ratio was expressed for a 1‐SD increment in the distribution of the logarithm of the biomarker. A univariate analysis and 2 multivariate models were considered. The multivariate model (model A) was adjusted for cardiovascular risk factors: age, sex, body mass index, smoking status, history of hypertension, personal history of cardiovascular disease, left ventricular hypertrophy, diabetes mellitus duration, glycated hemoglobin, use of statins, total cholesterol, HDL‐cholesterol, abnormal urinary albumin‐to‐creatinine ratio. We tested each model for log‐linearity and proportionality assumptions. We conducted a sensitivity analysis by using the competing risk model of Fine and Gray to estimate the subdistribution hazard ratios for MACE while accounting for the competing risk of noncardiovascular deaths.[22](#jah32947-bib-0022){ref-type="ref"}

Generalized c‐statistics were calculated for model A, accounting for variable follow‐up times. Comparisons of model adequacy were assessed using the likelihood ratio chi‐squared tests.[23](#jah32947-bib-0023){ref-type="ref"} The relative integrated discrimination improvement index was calculated to assess the improvement in 5‐year risk prediction of each biomarker in addition to traditional risk factors (model A).[24](#jah32947-bib-0024){ref-type="ref"} Five‐year risk was selected because it approximates the median follow‐up time for MACE.

*P*\<0.05 was considered statistically significant. Analyses were conducted using SAS version 9.4 (SAS Inc, Cary, NC).

Results {#jah32947-sec-0022}
=======

Baseline Characteristics {#jah32947-sec-0023}
------------------------

Overall, 1468 T2D patients were included in the SURDIAGENE study, with data from 1 subject not available for technical reasons. Baseline characteristics of the 1467 patients included in the analyses, including the levels of the 6 studied redox markers, are given in Table [1](#jah32947-tbl-0001){ref-type="table-wrap"}. Correlations of the biomarkers with clinical parameters are given in Table [2](#jah32947-tbl-0002){ref-type="table-wrap"}. Overall, only 6 of the 15 tested associations were statistically significant, indicating that the markers bring different information. AGEs, carbonyls, IMA, and OxHLIA were negatively associated with eGFR.

###### 

Baseline Characteristics

  Variables                                                         n=1467
  ----------------------------------------------------------------- --------------------------
  Male sex, n (%)                                                   847 (58)
  Age, y                                                            65±11
  Body mass index, kg/m^2^                                          31±6
  BMI ≥30 kg/m^2^, n (%)                                            830 (57)
  Active smoking, n (%)                                             153 (11)
  Diabetes mellitus duration, y                                     13 (6‐21)
  HbA~1c~, %                                                        7.8±1.5
  Serum creatinine, μmol/L                                          83 (34)
  eGFR, mL/min per 1.73 m^2^                                        72.7±25.1
  uACR, mg/mmol                                                     3 (1‐14)
  History of myocardial infarction, n (%)                           224 (15)
  History of stable angina, n (%)                                   256 (17)
  History of transient ischemic attack, n (%)                       127 (9)
  History of amputation, n (%)                                      73 (5)
  History of coronary artery revascularization, n (%)               219 (15)
  History of carotid artery revascularization, n (%)                35 (2)
  History of peripheral artery revascularization, n (%)             73 (5)
  History of atrial fibrillation, n (%)                             71 (5)
  Hypertension, n (%)                                               1274 (87)
  Systolic blood pressure, mm Hg                                    132.5±17.7
  Diastolic blood pressure, mm Hg                                   72.4±11.1
  Total cholesterol, mmol/L                                         4.8±1.2
  HDL cholesterol, mmol/L                                           1.2±0.4
  LDL cholesterol, mmol/L                                           2.7±1.0
  Resting heart rate, beats/min                                     71±14
  Left ventricular hypertrophy, n (%)                               237 (17)
  Use of metformin, n (%)                                           690 (47)
  Use of insulin, n (%)                                             882 (60)
  Use of statins, n (%)                                             666 (45)
  Use of β blockers, n (%)                                          498 (34)
  Fluorescent AGEs (AU)[a](#jah32947-note-0004){ref-type="fn"}      112 027 (92 969‐133 082)
  AOPP (chloramin T equiv)[a](#jah32947-note-0004){ref-type="fn"}   129 (52‐278)
  ELISA carbonyls, mmol/mg[a](#jah32947-note-0004){ref-type="fn"}   28.3 (25.9‐30.9)
  IMA (AU)[a](#jah32947-note-0004){ref-type="fn"}                   0.52 (0.34‐0.64)
  OxHLIA (V50 min)[a](#jah32947-note-0004){ref-type="fn"}           413 (353‐481)
  TRCP (gallic acid equiv)[a](#jah32947-note-0004){ref-type="fn"}   120 (103‐146)

AGEs indicates advanced glycation end products; AOPP, advanced oxidation protein products; AU, arbitrary unit; BMI, body mass index; eGFR, estimated glomerular filtration rate; ELISA, enzyme‐linked immunosorbent assay; equiv, equivalents; HbA~1c~, glycated hemoglobin; HDL, high‐density lipoprotein; IMA, ischemia‐modified albumin; LDL, low‐density lipoprotein; OxHLIA, oxidative hemolysis inhibition assay; TRCP, total reductive capacity of plasma; uACR, urine albumin‐creatinine ratio.

Below limit of detection AOPP 529, carbonyls 1, IMA 11, OxHLIA 11, TRCP 104. Data are shown as means±SD, median (25th‐75th percentiles), or n (%).

###### 

Spearman Correlations Between Redox Biomarkers and Clinical Parameters (Rho and *P* Value)

                               Fluorescent AGEs                                          AOPP             Carbonyls                                                 IMA                                                       OxHLIA                                                    TRCP
  ---------------------------- --------------------------------------------------------- ---------------- --------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------
  Age                          0.16 (\<0.0001)[a](#jah32947-note-0006){ref-type="fn"}    0.01 (0.7885)    0.09 (0.0007)[a](#jah32947-note-0006){ref-type="fn"}      0.03 (0.324)                                              0.07 (0.0126)[a](#jah32947-note-0006){ref-type="fn"}      0.04 (0.1017)
  Sex                          0.02 (0.4934)                                             −0.05 (0.1076)   −0.002 (0.9487)                                           −0.03 (0.2262)                                            0.02 (0.5055)                                             −0.01 (0.8138)
  Diabetes mellitus duration   0.06 (0.0172)                                             −0.01 (0.7487)   0.10 (\<0.0001)[a](#jah32947-note-0006){ref-type="fn"}    0.11 (\<0.0001)[a](#jah32947-note-0006){ref-type="fn"}    −0.002 (0.9362)                                           0.06 (0.0308)[a](#jah32947-note-0006){ref-type="fn"}
  BMI                          −0.06 (0.0146)[a](#jah32947-note-0006){ref-type="fn"}     0.03 (0.3024)    −0.02 (0.4233)                                            −0.06 (0.024)[a](#jah32947-note-0006){ref-type="fn"}      0.04 (0.1526)                                             −0.02 (0.3856)
  HbA~1c~                      −0.10 (0.0003)[a](#jah32947-note-0006){ref-type="fn"}     0.04 (0.2465)    −0.0008 (0.9771)                                          −0.01 (0.8081)                                            −0.08 (0.0018)[a](#jah32947-note-0006){ref-type="fn"}     −0.01 (0.7336)
  MAP                          −0.004 (0.8685)                                           0.04 (0.1742)    0.05 (0.0359)[a](#jah32947-note-0006){ref-type="fn"}      0.06 (0.0294)[a](#jah32947-note-0006){ref-type="fn"}      −0.05 (0.043)[a](#jah32947-note-0006){ref-type="fn"}      −0.01 (0.6845)
  GFR                          −0.34 (\<0.0001)[a](#jah32947-note-0006){ref-type="fn"}   −0.03 (0.4334)   −0.11 (\<0.0001)[a](#jah32947-note-0006){ref-type="fn"}   −0.12 (\<0.0001)[a](#jah32947-note-0006){ref-type="fn"}   −0.10 (\<0.0001)[a](#jah32947-note-0006){ref-type="fn"}   −0.03 (0.3526)
  ACR                          0.17 (\<0.0001)[a](#jah32947-note-0006){ref-type="fn"}    0.05 (0.1566)    0.08 (0.0018)[a](#jah32947-note-0006){ref-type="fn"}      0.06 (0.0313)[a](#jah32947-note-0006){ref-type="fn"}      0.08 (0.0019)[a](#jah32947-note-0006){ref-type="fn"}      0.06 (0.0232)[a](#jah32947-note-0006){ref-type="fn"}

ACR indicates urinary albumin/creatinine ratio; AGEs, advanced glycation end products; AOPP, advanced oxidation protein products; BMI, body mass index; GFR, glomerular filtration rate; HbA~1c~, glycated hemoglobin; IMA, ischemia‐modified albumin; MAP, mean arterial pressure; OxHLIA, oxidative hemolysis inhibition assay; TRCP, total reductive capacity of plasma.

*P*\<0.05.

Follow‐Up Data {#jah32947-sec-0024}
--------------

The median duration of follow‐up was 64 months. During the follow‐up, 354 participants presented a MACE (incidence rate of 4.3 events per 100 person‐years, among whom 267 died from cardiovascular cause, 107 presented a nonfatal myocardial infarction, and 74 had a nonfatal stroke) and 447 died from any cause (incidence rate of 5.2 per 100 person‐years).

Kaplan‐Meier survival curves for the outcome of MACE by tertiles of biomarker concentrations/activity of the biomarkers are presented in [Figure](#jah32947-fig-0001){ref-type="fig"}, and the univariate hazard ratios for MACE occurrence are given for each redox marker in Table [3](#jah32947-tbl-0003){ref-type="table-wrap"}. In univariate analyses, only fluorescent AGEs and carbonyl levels were associated with cardiac events, unlike IMA, OxHLIA, TRCP, and AOPP. Multivariate analysis including the traditional risk factors for MACE is also presented in Table [3](#jah32947-tbl-0003){ref-type="table-wrap"}. When tested, neither AGEs nor carbonyls remained independently associated with MACE occurrence. We found no significant statistical interaction between the obesity status and each biomarker in the multivariate models, suggesting no different association between redox biomarkers and outcome according the presence of obesity (data not shown).

![Kaplan‐Meier cumulative incidence curves for major adverse cardiovascular event by tertiles (dotted line, lowest tertile; dashed line, middle tertile; solid line, highest tertile) of (A) AGE,*P*=0.0002; (B) AOPP,*P*=0.5247; (C) carbonyls, *P*=0.0032; (D) IMA,*P*=0.18; (E) OxHLIA,*P*=0.097, (F) TRCP,*P*=0.37 or by groups (dotted line, below limit of detection; dashed line, below detected median; solid line, above detected median for B) AOPP,*P*=0.52. AGEs indicates advanced glycation end products; AOPP, advanced oxidation protein products; IMA, ischemia‐modified albumin; MACE, major adverse cardiovascular events; OxHLIA, oxidative hemolysis inhibition assay; TRCP, total reductive capacity of plasma.](JAH3-7-e007397-g001){#jah32947-fig-0001}

###### 

Hazard Ratios and 95% Confidence Interval for Major Adverse Cardiovascular Event According to Each Redox Biomarker

                       Univariate         Model A                                                              
  -------------------- ------------------ ------------------------------------------------- ------------------ -----------------------------------------------
  Fluorescent AGEs                                                                                             
  Per SD               1.38 (1.24‐1.54)   \<0.0001[a](#jah32947-note-0008){ref-type="fn"}   1.08 (0.96‐1.21)   0.2189
  Tertile 1            Reference          0.0002[a](#jah32947-note-0008){ref-type="fn"}     Reference          0.2862
  Tertile 2            1.26 (0.97‐1.63)                                                     1.22 (0.93‐1.61)   
  Tertile 3            1.72 (1.33‐2.23)                                                     1.03 (0.77‐1.37)   
  AOPP                                                                                                         
  Undetected           Reference          0.5263                                            Reference          0.0881
  Detected \< median   1.08 (0.83‐1.4)                                                      1.03 (0.77‐1.36)   
  Detected ≥ median    0.93 (0.72‐1.21)                                                     0.77 (0.57‐1.04)   
  Carbonyls                                                                                                    
  Per SD               1.15 (1.04‐1.27)   0.006[a](#jah32947-note-0008){ref-type="fn"}      1.03 (0.93‐1.15)   0.533
  Tertile 1            Reference          0.0034[a](#jah32947-note-0008){ref-type="fn"}     Reference          0.0268[a](#jah32947-note-0008){ref-type="fn"}
  Tertile 2            0.89 (0.68‐1.17)                                                     0.75 (0.56‐0.99)   
  Tertile 3            1.34 (1.05‐1.72)                                                     1.07 (0.82‐1.40)   
  IMA                                                                                                          
  Per SD               1.04 (0.92‐1.17)   0.584                                             0.96 (0.85‐1.08)   0.473
  Tertile 1            Reference          0.1839                                            Reference          0.9058
  Tertile 2            1.14 (0.86‐1.50)                                                     1.07 (0.80‐1.43)   
  Tertile 3            1.27 (0.98‐1.65)                                                     1.03 (0.78‐1.36)   
  OxHLIA                                                                                                       
  Per SD               1.05 (0.93‐1.18)   0.465                                             1.01 (0.89‐1.14)   0.9
  Tertile 1            Reference          0.0987                                            Reference          0.7099
  Tertile 2            1.19 (0.92‐1.54)                                                     0.94 (0.72‐1.24)   
  Tertile 3            1.33 (1.03‐1.73)                                                     1.06 (0.8‐1.40)    
  TRCP                                                                                                         
  Per SD               1.00 (0.90‐1.12)   0.979                                             0.99 (0.88‐1.12)   0.888
  Tertile 1            Reference          0.375                                             Reference          0.6678
  Tertile 2            1.00 (0.76‐1.30)                                                     0.98 (0.73‐1.30)   
  Tertile 3            1.18 (0.90‐1.54)                                                     1.10 (0.83‐1.47)   

Data are presented as hazard ratio (95% confidence interval). Model A: adjusted for age, sex, BMI, smoking status, history of hypertension, history of macrovascular disease, LVH, diabetes duration, HbA~1c~, use of statin, total cholesterol, HDL‐cholesterol, abnormal uACR. AGEs indicates advanced glycation end products; AOPP, advanced oxidation protein products; CI, confidence interval; HbA~1c~, glycated hemoglobin; HDL, high‐density lipoprotein; HR, hazard ratio; IMA, ischemia‐modified albumin; LVH, left ventricular hypertrophy; OxHLIA, oxidative hemolysis inhibition assay; TRCP, total reductive capacity of plasma; uACR, urine albumin/creatinine ratio.

*P*\<0.05.

After the competing risk of noncardiovascular death was accounted for in a Fine and Gray analysis (Table [S1](#jah32947-sup-0001){ref-type="supplementary-material"}) results were largely unchanged.

Discrimination and reclassification data are presented in Table [4](#jah32947-tbl-0004){ref-type="table-wrap"}. When integrated in a predictive model including classical risk factors, the markers did not allow proper reclassification of a significant part of the participants or improvement of the model discrimination.

###### 

C‐Statistics and 5‐Year Relative Integrated Discrimination Improvement Index Using Biomarkers in Addition to Traditional Risk Factors for the Prediction of Adverse Cardiovascular Event for the Cox Model With and Without Biomarkers

                     C‐Statistics With Biomarker   Difference in C‐Statistics[a](#jah32947-note-0010){ref-type="fn"} (95% CI)   Log‐Likelihood Ratio Test *P* Value   Relative IDI (95% CI)
  ------------------ ----------------------------- ---------------------------------------------------------------------------- ------------------------------------- -----------------------
  Fluorescent AGEs                                                                                                                                                    
  Tertiles           0.747                         0                                                                            0.84                                  −0.002
  Per SD             0.748                         0.001                                                                        0.22                                  −0.006
  Carbonyls                                                                                                                                                           
  Tertiles           0.748                         0.001                                                                        0.51                                  0.005
  Per SD             0.748                         0.001                                                                        0.54                                  0.002

AGEs indicates advanced glycation end products; BMI, body mass index; CI, confidence interval; HDL, high‐density lipoprotein; IDI, integrated discrimination improvement index; LVH, left ventricular hypertrophy; uACR, urine albumin/creatinine ratio.

C‐statistics reference for model including age, sex, BMI, smoking status, history of hypertension, history of cardiovascular disease, LVH, diabetes mellitus duration, HbA~1c~, use of statin, total cholesterol, HDL‐cholesterol, abnormal uACR, =0.747.

Discussion {#jah32947-sec-0025}
==========

Our main findings suggest no prognostic role of the 6 studied biomarkers or MACE prediction.

First, we found some negative results concerning several potential redox biomarkers that had never or scarcely been studied before to optimize cardiac prognosis in T2D. We showed that AOPP, OxHLIA, IMA, and TRCP were neither associated with the risk of MACE in our cohort. To our best knowledge, AOPP, OxHLIA, and IMA markers had never been studied for the prediction of cardiac or cardiovascular adverse events, and TRCP has recently been reported to be associated with coronary artery disease incidence in a relatively small cohort of T2D patients.[25](#jah32947-bib-0025){ref-type="ref"} However, it does not seem to be a promising marker in our study.

Second, we found that fluorescent AGEs and carbonyls were both significantly associated with MACE in univariate analyses but not after adjustment for classical risk factors, diabetes duration, and glycated hemoglobin. Because none of the studied markers appeared to be independently associated with MACE, we did not test the markers simultaneously in the model. Concerning carbonyls, they have been studied in human pediatric settings[11](#jah32947-bib-0011){ref-type="ref"} for predicting cardiac remodeling in heart failure[12](#jah32947-bib-0012){ref-type="ref"} or graft rejection after heart transplantation[26](#jah32947-bib-0026){ref-type="ref"} but not to our knowledge for predicting cardiac events in T2D.

Fluorescent AGEs are the most often studied of oxidative stress markers selected in the present study. They have been shown to be associated with angiographic severity of CAD,[27](#jah32947-bib-0027){ref-type="ref"} restenosis,[28](#jah32947-bib-0028){ref-type="ref"} heart failure,[29](#jah32947-bib-0029){ref-type="ref"}, [30](#jah32947-bib-0030){ref-type="ref"} and adverse clinical outcome in patients with diabetes mellitus undergoing percutaneous coronary intervention.[8](#jah32947-bib-0008){ref-type="ref"} Assessment of AGE levels by fluorescence is rather inexpensive and reproducible. This method targets pentosidine and crosslinks between free amino‐groups such as lysine and glucose, the fluorescence being chiefly associated with high‐molecular‐weight proteins such as albumin.[31](#jah32947-bib-0031){ref-type="ref"} However, epidemiological evidence for an association between high levels of plasma AGEs and increased cardiovascular risk has remained inconclusive to date. Associations between AGEs and cardiac events have been reported since early 2000s, first in case‐control studies[7](#jah32947-bib-0007){ref-type="ref"}, [32](#jah32947-bib-0032){ref-type="ref"}, [33](#jah32947-bib-0033){ref-type="ref"} then in a Finnish cohort of nondiabetics with an 18‐year follow‐up.[34](#jah32947-bib-0034){ref-type="ref"} In the latter report, there was a weak association between AGEs and coronary heart disease mortality, restricted to women and not taking as many covariates into account as in our study. More recently, AGEs and incident cardiovascular events were strongly associated in a case‐cohort study.[35](#jah32947-bib-0035){ref-type="ref"} Conversely, some studies were negative, reporting no association between AGEs and MACE, such as in a post hoc analysis of the ADVANCE study,[7](#jah32947-bib-0007){ref-type="ref"} in accordance with our study. Inconsistencies in previous literature may be due to heterogeneous variable adjustment for such confounders. Moreover, we demonstrated that AGEs provided no additional information that could allow an improvement in the accuracy of risk stratification for individuals in primary or secondary prevention, over the recommended risk scores.

Because the role of biomarkers related to the redox process is discussed in the case of prior renal replacement or significant chronic kidney disease, we examined if our negative results could have been due to the inclusion of such subjects in our study. At baseline, 1361 (90%) participants had no history of renal replacement therapy and an eGFR \>30 mL/min. When reanalyzing our data in these patients as a sensitivity analysis, we found no association between any biomarker and MACE risk, with no substantial difference from the results presented in Table [3](#jah32947-tbl-0003){ref-type="table-wrap"} (data not shown).

Some limitations must be acknowledged. First, our hospital‐based recruitment could possibly lead to a selection of patients with a high cardiovascular risk or more frequent comorbidities. However, risk score levels were similar to those observed in some population‐based cohort studies.[36](#jah32947-bib-0036){ref-type="ref"} Moreover, because of its single‐center recruitment, generalization of the results to other populations must be cautiously considered. Finally, measurements were performed only at baseline and can vary over time and environmental changes, making a definite causality link hard to establish, even though our prospective design is a clear asset for such an issue.

Our main strengths are the large number of subjects and events observed and the variety of covariates and risk factors. Moreover, our main goal was not to validate a novel or already existing biomarker. It focused on a global set of redox biomarkers that involve different physicochemical pathways and various ways to approach oxidative stress. A large and heterogeneous panel of biomarkers can be found in the literature, resulting from ROS production and subsequent modification of proteins, lipids, or DNA, but also more integrative markers reflecting the global imbalance between pro‐ and antioxidants in plasma (such as the total reductive capacity), but none has studied these types of biomarkers taken all together. For example, OxLIA and TRCP provide a picture of global systemic redox state, whereas carbonyls target all oxidized proteins, fluoAGEs imply a glycation component, and AOPP and IMA focus on more specific types of proteins modified by interaction with ROS (ie, tyrosine‐containing proteins or albumin). Actually, TRCP and OxHLIA constitute integrative and functional biomarkers reflecting the imbalance between the levels of both endogenous and exogenous antioxidants and those of pro‐oxidants such as ROS. Similarly to biochemical assays measuring AGEs, AOPP, carbonyls, and IMA, both TRCP and oxHLIA tests are simple, fast and do not require specialized equipment. Of note, factors determining the clinical use of a biomarker include the specificity, sensitivity, and reproducibility of the assay and also the ease and the cost of the assay.[15](#jah32947-bib-0015){ref-type="ref"} In addition, we decided to test both already developed markers with existing scientific background and dosage kits (such as AGEs) and experimental markers for which we had to develop more complex methods of determination.

In conclusion, we found no independent association between 6 redox biomarkers widely exploring oxidative stress pathways and the risk of incident MACE or all‐cause death. Moreover, these markers did not significantly improve risk discrimination and risk reclassification. A better understanding of the role of oxidative stress in atherosclerosis remains a challenge, and our results do not support clinical implementation of these markers or possible therapeutic applications.
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